



Off-label Uses of GLP-1 Agonists

Cassandra Kruse, PharmD

PGY2 Pharmacy Resident, Global Health

UPMC Presbyterian

Continuing Education Information

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides **1.0 contact hours** of continuing pharmacy education credit

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Disclosures

No members of the planning committee, speakers, presenters, authors, content reviewers, and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity of producing, marketing, re-selling, or distributing health goods or services, used on, or consumed by patients to disclose.

Disclaimer

The information presented at this Center for Continuing Education in Health Sciences program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Learning Objectives

1. Describe the relative benefits of GLP-1 agonist use in non-FDA approved indications of weight-related co-morbidities.
2. Repeat the proposed mechanism of action for GLP-1 agonist use in movement disorders.
3. Identify the benefits and limitations of GLP-1 agonist use in cognitive function disorders.